Profiling of genotoxic impurities in a lidocaine hydrochloride injection

XIAN Zhiran; SUN Chunmeng; LUO Xuefang; ZHONG Wenying

doi:10.11665/j.issn.1000-5048.20200412

Journal of China Pharmaceutical University > 2020 > 51(4): 466-471. > DOI: 10.11665/j.issn.1000-5048.20200412

XIAN Zhiran, SUN Chunmeng, LUO Xuefang, ZHONG Wenying. Profiling of genotoxic impurities in a lidocaine hydrochloride injection[J]. Journal of China Pharmaceutical University, 2020, 51(4): 466-471. DOI: 10.11665/j.issn.1000-5048.20200412

Citation:

PDF (967 KB)

Profiling of genotoxic impurities in a lidocaine hydrochloride injection

1.
Drug Quality Research Center, College of Science, China Pharmaceutical University
2.
School of Pharmacy, China Pharmaceutical University, China

More Information

Received Date: March 19, 2020

Graphical Abstract

Abstract

Abstract

This page contains the following errors:
error on line 1 at column 1: Start tag expected, '<' not found
Below is a rendering of the page up to the first error.
- lidocaine hydrochloride injection,
- genotoxic impurities,
- LC-MS/MS

FullText(HTML)

References (20)

References

[1]	Long J, Etxeberria AE, Nand AV, et al. A 3D printed chitosan-pectin hydrogel wound dressing for lidocaine hydrochloride delivery[J]. Mater Sci Eng C Mater Biol Appl,2019,104:109873. doi: 10.1016/j.msec.2019. 109873.
[2]	Chen YQ, Hong BH, Yi RZ. HPLC determination of contents and related substances in the tetrodotoxin lidocaine hydrochloride for injection[J]. Chin J Mar Drugs（中国海洋药物）, 2016,35(3): 67-75.
[3]	Wang X, Li X, Xiao Y. A novel dispersive liquid-liquid microextraction method with high performance liquid chromatography for detection of 2,6-dimethylaniline in lidocaine hydrochloride injection[J]. Se Pu,2018,36(3): 292-298.doi: 10.3724/SP.J.1123.2017.11049.
[4]	Deng ZH, Li AH, Hu WJ. Improvement of quality control of lidocaine hydrochloride injection[J]. J Pharm Pract（药学实践杂志）,2016(1):72-75.doi: 10.3969/j.issn.1006-0111.2016. 01. 019.
[5]	Chinese Pharmacopoeia Commission. Chinese Pharmacopoeia: Part 2(中华人民共和国药典:二部) [S]. Beijing: China Medical Science Press,2015:979-980.
[6]	European Pharmacopeia 9.0:Volume III（欧洲药典9.0:卷3）[S]. France: European Directorate for the Quality of Medicine & Healthcare,2017:2905-2906.
[7]	The United States Pharmacopoeial Convention. United States Pharmacopoeia 40[S]. Rockville: The United States Pharmacopeial Convention,2017:4847-4848.
[8]	Yang RY, Yin XL, Liang M, et al. Microscale experimental study on preparation of lidocaine[J]. Guangdong Chem Ind（广东化工）,2010,37 (5):137, 149.doi: 10.3969/j.issn.1007-1865.2010.05.058.
[9]	Zhejiang Huineng Biological Co., Ltd. Method for preparing lidocaine hydrochloride： 201510738390.7[P].2016-02-03.
[10]	Bengbu Fengyuan Pharmaceutical Technology Development Co., Ltd. Method for preparing lidocaine： 201010579590.X[P].2011-05-25.
[11]	Li M. Organic Chemistry of Drug Degradation[M]. United Kingdom: CPI Group (UK) Ltd, Croydon, CR04YY, UK,2012.
[12]	Li Q, Magers T, King B, et al. Measurement of lidocaine and 2,6-dimethylaniline in minipig plasma, skin, and dermal tapes using UHPLC with electrospray MS/MS[J]. J Chromatogr B Analyt Technol Biomed Life Sci,2018,1087-1088:158-172. doi: 10.1016/j.jchromb.2018.04.030.
[13]	Kobets T, Duan JD, Brunnemann KD, et al. DNA-damaging activities of twenty-four structurally diverse unsubstituted and substituted cyclic compounds in embryo-fetal chicken livers[J]. Mutat Res, 2019,844:10-24.doi: 10.1016/j.mrgentox.2019.06.004.
[14]	Koujitani T., Yasuhara K., Kobayashi H., et al. Tumor‐promoting activity of 2,6‐dimethylaniline in a two‐stage nasal carcinogenesis model in N‐bis(2‐hydroxypropyl) nitrosamine‐treated rats[J]. Cancer Lett, 1999,142(2):161-171.
[15]	The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Trepartite Guideline: Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk M7(R1) [S/OL]. (2017-05-01) [2019-01-28]. https://www.ich.org/fileadmin/.
[16]	Heewon L. Pharmaceutical industry practices on genotoxic impurities[M]. US: CRC, 2015:87-88.
[17]	Andrew T．Genotoxic impurities strategies for identification and control[M]. Canada: John Wiley & Sons, Inc., Hoboken, New Jersey, 2011: 44-46.
[18]	Benigni R, Bossa C. Structure alerts for carcinogenicity, and the Salmonella assay system: a novel insight through the chemical relational databases technology[J]. Mutat Res,2008,659(3):248-261. doi: 10.1016/j.mrrev.2008.05.003.
[19]	Xia YL, Zhang AJ, Liu JP. Optimization of tiopronin formulation[J]. Centr South Pharm（中南药学）, 2015,13(7):739-740,779.
[20]	Lei XX, Wang Y, Zhang JL, et al. Analysis of the addition and measurement of bacteriostatics and antioxidants in injection and eye drops[J]. Mod Chem Res（当代化工研究）,2017 (4):143-144.

[1]	YE Zhenning, WU Zhenghong, ZHANG Huaqing. Research progress of blood-brain barrier crossing strategies and brain-targeted drug delivery mediated by nano-delivery system[J]. Journal of China Pharmaceutical University, 2024, 55(5): 590-602. DOI: 10.11665/j.issn.1000-5048.2024052202
[2]	LUO Xuelian, WU Chengsheng, ZHA Cheng, LIU Sheng. Research progress and prospects of implantable drug delivery systems for postoperative tumor therapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 538-547. DOI: 10.11665/j.issn.1000-5048.2024040901
[3]	WANG Shihao, LIU Lifeng, DING Yang, LI Suxin. Research progress of pH-responsive drug delivery systems in cancer immunotherapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 522-529. DOI: 10.11665/j.issn.1000-5048.2024011902
[4]	YU Jiayu, LIN Zezhi, CAO Wei, ZHANG Jianjun, WEI Yuanfeng, GAO Yuan, QIAN Shuai. Research progress of bio-metal organic frameworks in drug delivery system[J]. Journal of China Pharmaceutical University, 2023, 54(1): 23-33. DOI: 10.11665/j.issn.1000-5048.20221111003
[5]	ZHOU Yeshu, WANG Yanmei, ZHANG Beiyuan, WU Shuaicong, YANG Lei, YIN Lifang. Research progress of inorganic nanomaterials in drug delivery system[J]. Journal of China Pharmaceutical University, 2020, 51(4): 394-405. DOI: 10.11665/j.issn.1000-5048.20200403
[6]	LI Haoxian, LIN Huaqing, CHEN Jingwen, WANG Liyuan. Research progress of carbon nanomaterials in cancer drug delivery[J]. Journal of China Pharmaceutical University, 2019, 50(1): 100-106. DOI: 10.11665/j.issn.1000-5048.20190114
[7]	FAN Qianqian, XING Lei, QIAO Jianbin, ZHANG Chenglu, JIANG Hulin. Advances in drug delivery systems for the treatment of liver fibrosis[J]. Journal of China Pharmaceutical University, 2018, 49(3): 263-271. DOI: 10.11665/j.issn.1000-5048.20180302
[8]	CHEN Xing, KANG Yang, WU Jun. Advances in biodegradable functional polymers based protein drug delivery system[J]. Journal of China Pharmaceutical University, 2017, 48(2): 142-149. DOI: 10.11665/j.issn.1000-5048.20170203
[9]	WANG Yazhe, ZHOU Jianping, DING Yang, WANG Wei. Advances in research of biomimetic drug delivery systems[J]. Journal of China Pharmaceutical University, 2014, 45(3): 267-273. DOI: 10.11665/j.issn.1000-5048.20140303
[10]	TANG Yue, KE Xue. Advances of mesoporous silica nanoparticles as drug delivery system[J]. Journal of China Pharmaceutical University, 2012, 43(6): 567-572.

Cited By

Cited by

Periodical cited type(0)

Other cited types(2)

Get Citation

PDF

XML

Article views (344) PDF downloads (981) Cited by(2)

Turn off MathJax

Article Contents

Abstract

References

Profiling of genotoxic impurities in a lidocaine hydrochloride injection

Abstract

This page contains the following errors:

Below is a rendering of the page up to the first error.

References

Related Articles

Cited by

Periodical cited type(0)

Other cited types(2)

Catalog

Profiling of genotoxic impurities in a lidocaine hydrochloride injection

Abstract

This page contains the following errors:

Below is a rendering of the page up to the first error.

References

Related Articles

Cited by

Periodical cited type(0)

Other cited types(2)

Catalog

Export File

Citation

Format

Content